Business
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN. BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today annou
About this update from Vera Therapeutics, Inc.
[{"type":"image","alt":"Vera Therapeutics","displaySize":"","headline":null,"caption":"Vera Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/72a8e9e8ecc86f0d9732b38c0cd327c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6..aCv7B4Q_6wAcqlLyx_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/72a8e9e8ecc86f0d9732b38c0cd327c5","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"FDA assigned PDUFA target action date of July 7, 2026.","length":54,"tagName":"p"}]},{"val":[{"type":"text","content":"If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN.","length":82,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":234,"olType":false},{"type":"text","content":"BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the atacicept Biologics License Application (BLA) for the treatment of adults with immunoglobulin A nephropathy (IgAN) was accepted for Priority Review by the U.S. Food and Drug Administration (FDA). The BLA, which was submitted using the Accelerated Approval Program, was assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2026. If approved, atacicept could offer patients an autoinjector for at-home self-administration of a once-weekly subcutaneous injection.","length":761,"tagName":"p"},{"type":"text","content":"“Atacicept offers a distinct approach through dual targeting of BAFF and APRIL, which we believe could advance the standard of care in IgAN, if approved,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “FDA’s Priority Review designation reinforces the need for new therapies that can reshape the IgAN treatment landscape. We remain committed to working with the FDA to facilitate a thorough review of the BLA. Our team is focused on bringing a potential treatment to patients with the...